BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

Part of paid clinical trials in Columbus, Ohio.

Sponsor
Luminary Therapeutics
Study ID
NCT06340750
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • LMY-920 — BIOLOGICAL
    CAR T Therapy

Study Details

This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores.

Key Dates

Start date
Apr 1, 2025
Status verified
May 2025
Primary completion
Apr 15, 2026
Completion
Jun 15, 2026

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: BAFF CAR T
    Autologous BAFF CAR T Therapy

Primary Outcome Measure

Safety of the Treatment [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Nationwide Children'sColumbusOhio43205-

Find similar trials in Columbus, OH

By condition
Lupus (SLE)
By specialty
RheumatologyAutoimmune disease
By research site
Nationwide Children's· Columbus, OH

Related Studies